Which Country Is Cerezyme (Imiglucerase) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Cerezyme (imiglucerase) is a 400-unit lyophilised vial reconstituted and given by intravenous infusion roughly every two weeks, for life, to patients with Gaucher disease type 1 — a rare inherited enzyme deficiency causing organ enlargement, bone disease and blood abnormalities. As with other lysosomal storage disorder therapies, there is no cure and no defined treatment endpoint, so the manufacturing, cold-chain and orphan-development costs behind Cerezyme are recovered across decades of continuous dosing rather than a finite treatment course. In Türkiye, the Ministry of Health anchors the reference price to the lowest ex-factory price found in a designated basket of EU member states, then converts it using the "pharmaceutical euro" (Dönemsel Avro Değeri) — fixed at 65% of the previous year's average Central Bank euro rate rather than the live spot rate. That mechanism, published via the TİTCK price list and gazetted in the Resmî Gazete, is a major reason Turkish list prices for orphan biologics sit structurally below free-pricing markets.

Gaucher disease is unusual among lysosomal disorders for having a genuinely competitive treatment landscape, though the competition varies by country. Two alternative enzyme replacement therapies, velaglucerase alfa (VPRIV) and taliglucerase alfa (Elelyso), are approved in various markets and can be used interchangeably with Cerezyme in some clinical settings, giving national payers leverage that they lack for single-source orphan biologics. Oral substrate-reduction therapies such as eliglustat and miglustat are also approved for a subset of patients in many countries, offering a non-infused alternative pathway. Where all of these options are reimbursed and available, competitive tendering can shape national procurement; where only Cerezyme is approved or reimbursed, that competitive pressure on price simply does not exist.

Germany evaluates Cerezyme under its AMNOG framework, where a manufacturer sets a free price for the first six months of a new indication before a negotiated price applies, backdated to month seven. The United Kingdom's NICE ordinarily applies a cost-per-QALY threshold that was raised from the long-standing £20,000–£30,000 band to £25,000–£35,000, announced 1 December 2025 and effective from April 2026 (see NICE) — but for a disease as rare as Gaucher type 1, NICE typically evaluates through its separate Highly Specialised Technologies (HST) programme, applying a distinct cost-effectiveness framework designed for conditions that cannot generate large randomised-trial evidence bases.

The United States has no equivalent government reference mechanism for a lifelong orphan biologic like Cerezyme: pricing is largely free at launch and negotiated privately between the manufacturer, payers and specialty pharmacy benefit managers. Most patients never encounter a list price directly because Cerezyme is dispensed through hospital or specialty infusion pharmacies under insurance or national-health-system funding, with substantial confidential rebates negotiated at the payer level. For the underlying mechanics of why Türkiye's published prices sit where they do, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Cerezyme I'm being offered genuine?

No falsified batches of Cerezyme have been recorded in WHO's alert series to date. That is a genuinely reassuring fact about this specific product's track record, but it is not a reason to relax verification: Cerezyme is a lifelong biologic dispensed almost exclusively through hospital and specialty infusion pharmacies, and any offer of it outside that channel — particularly across borders or through informal resellers — should be treated with the same scrutiny you would apply to any high-value cold-chain biologic.

Because multiple enzyme replacement options exist for Gaucher disease, patients sometimes switch products when local stock of one is constrained. That switching should always happen through the treating haematologist or metabolic specialist and a licensed pharmacy, not through an informal supplier offering whichever brand happens to be available — a distinction that matters more for verification than for clinical outcome.

• Scan the carton's GS1 DataMatrix and confirm it decodes to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch) — a code that will not scan, or scans to the wrong product, is a hard stop.
• If the vial is sourced in Türkiye, check that its karekod is notified to the national İlaç Takip Sistemi (İTS) track-and-trace system at its.saglik.gov.tr before it leaves the pharmacy.
• Ask for a continuous 2–8°C temperature log covering the actual shipment you are receiving, not a generic cold-chain certificate — Cerezyme must never be frozen or shaken.
• Confirm reconstitution takes place only in a licensed hospital or specialty infusion pharmacy immediately before administration, never pre-mixed and shipped.
• No falsified batches of Cerezyme have been logged in WHO's alert series to date; cross-check any concern against our WHO falsified medicine alerts tracker rather than assuming the absence of a listing means informal sourcing is safe.
• Be suspicious of any supplier offering Cerezyme, VPRIV or Elelyso interchangeably without a haematology or metabolic-disease prescription behind the switch.
• Review the full verification workflow in our guide to checking that a medicine is genuine.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Enzyme replacement therapies

Related high-cost medicines